Muschek L D, Grindel J M
J Clin Pharmacol. 1980 Apr;20(4):223-9. doi: 10.1002/j.1552-4604.1980.tb01702.x.
Zomepirac has been shown to be rapidly and completely absorbed after oral administration to man. Urinary excretion is the principal route for removal of zomepirac and its metabolites in man and in animals. Zomepirac is highly bound to plasma protein. The pharmacokinetics of zomepirac after single and multiple doses in man can be adequately described by a two-compartment oral absorption model. There is a linear relationship between dose and peak plasma concentration, AUC, and urinary excretion of zomepirac. The bioavailability of zomepirac was unaffected by single or repeated doses of antacid. The rhesus monkey has been shown to be a good predictive animal model for zomepirac's metabolism and pharmacokinetics in man, with glucuronidation found to be the principal route of metabolism in both species.
佐美酸经口服给药后，在人体内能迅速且完全地被吸收。在人和动物体内，尿液排泄是佐美酸及其代谢产物排出体外的主要途径。佐美酸与血浆蛋白高度结合。单剂量和多剂量给药后，人体内佐美酸的药代动力学可用双室口服吸收模型进行充分描述。佐美酸的剂量与血浆峰浓度、曲线下面积（AUC）以及尿液排泄量之间呈线性关系。抗酸剂单次或重复给药对佐美酸的生物利用度没有影响。恒河猴已被证明是预测佐美酸在人体内代谢和药代动力学的良好动物模型，在这两个物种中，葡萄糖醛酸化都是主要的代谢途径。
